Expand DRTS Menu
DRTS MENU

DRTS Latest Press Releases

-- July 15, 2026 --

Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center Globe Newswire 8:30 AM

-- June 25, 2026 --

Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet PRNewswire 11:35 AM

-- June 23, 2026 --

Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT at Hadassah University Medical Center in Israel Globe Newswire 8:30 AM

-- June 11, 2026 --

Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control Globe Newswire 8:30 AM

-- June 3, 2026 --

Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT Therapy to U.S. Urological Cancer Patients Globe Newswire 8:30 AM

-- June 1, 2026 --

Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting Globe Newswire 9:00 AM

-- May 18, 2026 --

Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update Globe Newswire 4:01 PM
Alpha Tau to Participate in May Investor Conferences Globe Newswire 8:30 AM

-- May 11, 2026 --

Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ET Globe Newswire 7:00 AM

-- May 8, 2026 --

Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma Globe Newswire 9:10 AM
Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT to Treat Recurrent Cutaneous Squamous Cell Carcinoma Globe Newswire 9:00 AM

-- May 7, 2026 --

Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Italy with Alpha DaRT at the University of Verona's Pancreas Institute Globe Newswire 9:00 AM

-- May 5, 2026 --

Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT Head and Neck Cancer Combination with Pembrolizumab Globe Newswire 9:14 AM

-- May 4, 2026 --

Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT Pancreatic Cancer Trials Presented at DDW 2026 Globe Newswire 9:17 AM

-- April 27, 2026 --

Alpha Tau Announces Presentation of Pancreatic Cancer Data at Upcoming ASCO Annual Meeting, Showcasing Combined Results from Three Alpha DaRT Pancreatic Cancer Studies Globe Newswire 9:01 AM

-- April 23, 2026 --

Alpha Tau Announces FDA Approval of IDE Supplement to Expand Alpha DaRT IMPACT Trial to Patients with Pancreatic Cancer Receiving Gemcitabine with Abraxane (Nab-Paclitaxel) Globe Newswire 9:02 AM
Alpha Tau Successfully Treats First Pancreatic Cancer Patient in Europe with Alpha DaRT in French Multicenter ACAPELLA Clinical Trial Globe Newswire 9:01 AM

-- March 31, 2026 --

Alpha Tau Announces First-Ever Oral Presentation of Alpha DaRT Pancreatic Cancer Data at Digestive Disease Week (DDW) 2026 Globe Newswire 9:15 AM

-- March 16, 2026 --

Alpha Tau to Present at Sidoti March Virtual Small Cap Conference Globe Newswire 10:02 AM

-- March 9, 2026 --

Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update Globe Newswire 4:02 PM

-- February 24, 2026 --

Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT in Unresectable Locally Advanced or Locally Recurrent Head and Neck Cancer Globe Newswire 9:00 AM
Market Data Delayed 15 Minutes